343 related articles for article (PubMed ID: 8289964)
1. Acute myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
Mesárosová A; Hrivnáková A; Babusíková O
Neoplasma; 1993; 40(6):341-5. PubMed ID: 8289964
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
Mesárosová A; Hrivnáková A; Klobusická M; Babusíková O
Neoplasma; 1995; 42(1):9-14. PubMed ID: 7617076
[TBL] [Abstract][Full Text] [Related]
3. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
4. A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas.
Mesárosová A; Hrivnáková A; Babusíková O
Neoplasma; 1995; 42(6):307-12. PubMed ID: 8592572
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
6. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
7. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
[TBL] [Abstract][Full Text] [Related]
9. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
Lewis RE; Cruse JM; Webb RN; Sanders CM; Beason K
Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD13 and CD33 surface antigen-negative acute myeloid leukemia.
Kraguljac N; Marisavljevic D; Jankovic G; Radosevic N; Pantic M; Donfrid M; Miletic N; Boskovic D; Colovic M
Am J Clin Pathol; 2000 Jul; 114(1):29-34. PubMed ID: 10884796
[TBL] [Abstract][Full Text] [Related]
11. Purine degradative enzymes and terminal transferase in acute myelogenous leukemia: clinical relevance.
Patmasiriwat P; Anukarahanonta T; Chinprasertsuk S
Ann Clin Lab Sci; 1993; 23(4):281-9. PubMed ID: 8373133
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
13. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
15. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
Zelezníková T; Babusíková O
Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
[TBL] [Abstract][Full Text] [Related]
16. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
17. Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital.
Ghosh S; Shinde SC; Kumaran GS; Sapre RS; Dhond SR; Badrinath Y; Ansari R; Kumar A; Mahadik S; Chougule AB; Nair CN
Indian J Cancer; 2003; 40(2):71-6. PubMed ID: 14716122
[TBL] [Abstract][Full Text] [Related]
18. Relation of some cytochemical activities to the expression of CD34 marker in acute leukemia.
Klobusická M; Babusíková O; Hrivnáková A
Neoplasma; 1993; 40(5):309-14. PubMed ID: 7505888
[TBL] [Abstract][Full Text] [Related]
19. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between immunological characteristics and prognosis in children with acute myeloid leukemia].
Gu LJ; Tie LJ; Jiang LM; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP; Ye H
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):241-5. PubMed ID: 19374802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
